Novartis | NVS - Debt


Novartis reported $32.02B in Debt for its fiscal quarter ending in September of 2025.





Debt Change Date
AbbVie USD 1000K 70.48B Sep/2025
Amgen USD 54.59B 1.62B Sep/2025
AstraZeneca USD 32.63B 207M Sep/2025
Bausch Health Companies USD 21.04B 696M Sep/2025
Biogen USD 6.29B 1.7M Dec/2025
Bristol-Myers Squibb USD 51.04B 112M Sep/2025
Canopy Growth CAD 259.33M 68.47M Sep/2025
Corcept Therapeutics USD 6.36M 247K Sep/2025
Drreddys Laboratories INR 67.73B 19.09B Dec/2025
Eli Lilly USD 42.51B 2.6B Sep/2025
Gilead Sciences USD 24.94B 5M Sep/2025
GlaxoSmithKline GBP 17.75B 396M Sep/2025
Glaxosmithkline GBP 17.75B 396M Sep/2025
J&J USD 45.8B 4.97B Sep/2025
Merck USD 41.37B 5.97B Sep/2025
Novartis USD 32.64B 1.37B Jun/2025
Novartis USD 32.02B 615M Sep/2025
Pacira USD 376.72M 203.77M Sep/2025
Perrigo USD 3.65B 454.7M Jun/2025
Pfizer USD 60.85B 78M Sep/2025
Phibro Animal Health USD 474.17M 730K Sep/2024
Prestige Brands USD 1.04B 1.7M Sep/2025
Roche Holding CHF 33.03B 1.41B Jun/2025
Sanofi EUR 21.76B 530M Sep/2025
Sanofi EUR 21.76B 530M Sep/2025
Supernus Pharmaceuticals USD 42.21M 10.44M Sep/2025
Zoetis USD 7.27B 482M Sep/2025